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Background: Efforts to develop malaria vaccines show promise. Mathematical model-based estimates of the
potential demand, public health impact, and cost and financing requirements can be used to inform investment
and adoption decisions by vaccine developers and policymakers on the use of malaria vaccines as complements to
existing interventions. However, the complexity of such models may make their outputs inaccessible to non-
modeling specialists. This paper describes a Malaria Vaccine Model (MVM) developed to address the specific needs
of developers and policymakers, who need to access sophisticated modeling results and to test various scenarios in
a user-friendly interface. The model’s functionality is demonstrated through a hypothetical vaccine.
Methods: The MVM has three modules: supply and demand forecast; public health impact; and implementation
cost and financing requirements. These modules include pre-entered reference data and also allow for user-defined
inputs. The model includes an integrated sensitivity analysis function. Model functionality was demonstrated by
estimating the public health impact of a hypothetical pre-erythrocytic malaria vaccine with 85% efficacy against
uncomplicated disease and a vaccine efficacy decay rate of four years, based on internationally-established targets.
Demand for this hypothetical vaccine was estimated based on historical vaccine implementation rates for routine
infant immunization in 40 African countries over a 10-year period. Assumed purchase price was $5 per dose and
injection equipment and delivery costs were $0.40 per dose.
Results: The model projects the number of doses needed, uncomplicated and severe cases averted, deaths and
disability-adjusted life years (DALYs) averted, and cost to avert each. In the demonstration scenario, based on a
projected demand of 532 million doses, the MVM estimated that 150 million uncomplicated cases of malaria and
1.1 million deaths would be averted over 10 years. This is equivalent to 943 uncomplicated cases and 7 deaths
averted per 1,000 vaccinees. In discounted 2011 US dollars, this represents $11 per uncomplicated case averted and
$1,482 per death averted. If vaccine efficacy were reduced to 75%, the estimated uncomplicated cases and deaths
averted over 10 years would decrease by 14% and 19%, respectively.
Conclusions: The MVM can provide valuable information to assist decision-making by vaccine developers and
policymakers, information which will be refined and strengthened as field studies progress allowing further
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Modeling can provide key input into public health deci-
sions to use, or not use, new health technologies in the
developing world [1,2]. Models provide data on a given
intervention’s impact, cost-effectiveness, and/or finan-
cing requirement estimates. Models allow analyses of
situations that are difficult or impossible to replicate in
real life, including in field trials, such as the absolute
impact of a new malaria control intervention in the
absence of any existing interventions. They can provide
insight by analyzing complex scenarios and identifying
which are most likely to occur and which parameters,
and their ranges, are the most influential [3]. It is
important that modeling estimates be made available to
support evidence-based decision-making. This paper
describes a new model for vaccines against malaria, a
disease that caused approximately 660,000 deaths in
2010, mostly of children in sub-Saharan Africa [4]. The
Malaria Vaccine Model (MVM) was designed to assist vac-
cine developers and policymakers in developing countries
and in global organizations to make informed decisions
about the design and adoption of malaria vaccines.
The demand for evidence on which policymakers and
developers can base decisions is increasing. Those devel-
oping new, often more expensive, public health interven-
tions for use in developing countries must invest in
interventions with the appropriate attributes (e.g., level
of efficacy, costs, mode of delivery) to realize desired
health impacts. Such decisions will need to be supported
by modeled estimates, such as potential impact and
financial requirements. The GAVI Alliance (GAVI) has
invested close to $100 million since 2000 in activities re-
lated to Haemophilus influenzae type B (Hib), pneumo-
coccal conjugate, and rotavirus vaccines. Establishing the
value of these vaccines through the generation of impact
estimates was one of the key activities, which arose from
the recognition that multi-year delays occurred in the
introduction of Hib vaccine by countries, in part because
of the lack of data on the burden of disease and potential
impact of vaccines [5]. Ensuring that global, regional,
and country decision makers have access to these data
in advance could improve the timeliness with which
future interventions reach those in need.
A number of models have recently been used to
estimate the impact of interventions worldwide. Some
were intended to inform global policies and have focused
on individual vaccines, such as human papilloma virus,
HIV, and rotavirus vaccines [6-8]. By contrast, the Lives
Saved Tool (LiST) estimated the impact of up to dozens
of child survival interventions (including malaria control
interventions) across 42 low- and middle-income coun-
tries worldwide [9]. This model, which was intended to
help global policymakers prioritize interventions, has
been extended for use in individual countries. TheProVac Initiative in the Americas included a model to
support country decision-making on the use of new
vaccines; the London School of Hygiene and Tropical
Medicine and the Swiss Tropical and Public Health
Institute (Swiss TPH) developed a web-based tool built
on modeled data to assist African policymakers in mak-
ing local decisions on the use of intermittent preventive
treatment of malaria in infants [10,11]. These examples
illustrate the importance of being clear about a model’s
purpose and target audiences, and of taking into account
the impact of multiple interventions against diseases.
A malaria vaccine model needs to inform vaccine de-
velopers as well as policy and financing decision-makers
at global, regional, and country levels. Among other re-
quirements, it needs to be linked to data on transmission
and epidemiology in each country and allow for the
consideration of malaria vaccines in the context of other
malaria interventions available to countries. Malaria vac-
cine models were recently reviewed by the World Health
Organization (WHO) [12]. There are two published dy-
namic models that estimate the potential impact of mal-
aria vaccines. One model has been under development
since 2003 at the Swiss TPH [13]. The second, more
recent, model was developed at Imperial College London
[14]. Both models consider the dynamics of malaria
transmission and of natural immunity to Plasmodium
falciparum using simulation approaches to reflect the
underlying relationship between interventions and
how much disease they may be able to avert. These
approaches can be difficult for non-modeling specialists
and policymakers to utilize. The WHO encourages
policymakers to include model based cost-effectiveness
estimates in support of eventual malaria vaccine adop-
tion decisions [15]. However, published economic
analyses of malaria vaccination based on such models
[16] so far have not considered supply-side consider-
ations, such as manufacturing capacity, which influence
implementation and ultimately impact on health.
With global efforts to develop malaria vaccines showing
promise, the PATH Malaria Vaccine Initiative (MVI)
worked with partners to develop a Malaria Vaccine Model
(MVM) that extended the Swiss TPH model by including
supply-side considerations and country-specific estimates,
and that allowed vaccine developers and policymakers to
more easily access the outputs of the Swiss TPH model.
The MVM was designed to fill a range of roles for differ-
ent audiences. For non-profit organizations working on
vaccine development, the MVM can help explore the
trade-offs in potential product characteristics as part of
informing and prioritizing R&D decisions. The MVM can
inform global and regional policymakers of the potential
impact associated with various delivery strategies and the
financing needs for malaria vaccines. At the country level,
it can assist local policymakers, for example, through
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potential impact of malaria vaccines in the context of
existing malaria control interventions.
The first version of the MVM was developed with the
Boston Consulting Group and Swiss TPH and utilized
by MVI and partners between 2005 and 2007 to inform
discussions regarding the establishment of an Advance
Market Commitment for malaria vaccines [17]. The
current version of the MVM, presented here, was devel-
oped between 2008 and 2010 by MVI in collaboration
with Swiss TPH and Applied Strategies. This version
reflects the understanding gained from experience with
the initial version about underlying model parameters
and design (including outputs), potential uses, and soft-
ware. The MVM uniquely integrates supply, demand,
and cost with public health impact estimates generated
from a dynamic malaria vaccine model, while presenting
both country-specific and global level data in a user-
friendly interface.
This paper describes the major design features, critical
parameters, and outputs of the MVM. A demonstration
scenario was created that is used to illustrate the model
functionality and is not intended to estimate the impact
of any specific malaria vaccine. While the modeled vac-
cine efficacy is substantially higher than the most clinic-
ally advanced malaria vaccine candidate today [18], this
demonstration scenario models a hypothetical vaccine
based on a strategic goal for the development of a
malaria vaccine set by the international community in
2006 through the Malaria Vaccine Technology Roadmap:
the development of a vaccine with protective efficacy of
more than 80% against clinical disease and lasting longer
than four years [19]. The results of this demonstration
scenario are presented, along with lessons learned for
the future development of similar models.
Methods
Overview of model structure
The MVM is composed of three distinct modules (Figure 1).
The first module, modeling vaccine supply and demand,
was developed by MVI and Applied Strategies. The second
module, based on Swiss TPH’s model simulations, esti-
mates the public health impact expected from different
malaria vaccines deployed in varying populations through
several modes of delivery. The third module uses data
from the first two modules and adds vaccine price and
cost of delivery to estimate the total investment that would
be required to achieve the potential public health gains
and costs per event averted. Each module includes a built-
in sensitivity analysis function for some key parameters
(e.g. vaccine price, year of vaccine availability).
As described above, one demonstration scenario using
a high efficacy vaccine was selected to illustrate the
model’s functionality. Descriptions of each module areprovided below, followed by descriptions of the input
values used in the demonstration scenario.
Software and interface
MVM was built as a Microsoft® Windows desktop applica-
tion using the Microsoft®. NET framework (version 3.5).
The criteria considered in the software selection process,
drawing on experience from the first version of the model,
were ease of use by non-experts, familiarity (similar to
Microsoft Windows), ability to interface well with large
datasets containing elements from the Swiss TPH model,
and ease of updating new reference datasets. Microsoft
Excel was used for the first version of the model, however
it was challenging to efficiently manage the complex data
underpinning the model, and it was less user-friendly.
Although the Microsoft®. NET software is proprietary, an
unrestricted license was granted for use in the MVM.
Model inputs are either selected from drop-down
menus or entered as numbers. The outputs include graph-
ics displayed on the screen, with an option to export data
into Excel for customized reports.
Supply and demand forecast
Based on user inputs and reference data, the supply
and demand forecast module predicts the quantity of
vaccines that will be available at a given time and the
number of doses that are in demand by countries
(Tables 1 and 2).
All countries with an annual average birth cohort esti-
mate and projection from the Population Division of
the Department of Economic and Social Affairs of the
United Nations (UN) as of 2008 were included in the
MVM. Results can be generated for both individual and
multiple countries at once. Users may create classifica-
tions and/or groupings of these countries for a particu-
lar analysis. For example, users could select only those
countries that are GAVI-funding eligible, they may
focus on high malaria disease burden countries in sub-
Saharan Africa, or they may generate estimates for a
single country.
Reference data
Population Data on the population of each country
(birth cohort, one-year olds, 0-4 year olds, 0-39 year
olds, and the total population) were drawn from the UN
Population Division [20], and are regularly updated with
the latest data, thereby accounting for changes in demo-
graphic trends. Users may select the age range of the tar-
get population consistent with the expected vaccination
strategies of potential malaria vaccines (Table 2).
Vaccine coverage The MVM included historical and
projected vaccine coverage for Bacille Calmette-Guerin;
first, second, and third doses of diphtheria-tetanus-
Figure 1 Structure of the Malaria Vaccine Model (MVM). This figure depicts the MVM structure. The central box contains the three modules
within the MVM: supply and demand forecast, public health impact estimates, and financial analysis. Above and below the MVM modules box are
two rectangles describing the underlying reference data accessed by the modules. Arrows represent the interaction between reference data and
user inputs and modules within the MVM, as well as between modules of the MVM.
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vaccine for each country. Users may set the maximum
vaccine coverage for each country equal to historical
data for any of the above vaccines, or they may set
maximum vaccine coverage at any level from 0–100%.
Data on the 2005–2007 coverage rates were obtained
from the WHO and United Nations Children’s Fund
(UNICEF) [21]. Future coverage levels for this analysis
were based on projections from WHO (Lara Wolfson,
WHO ICE-T v4.0, Oct 2007, unpublished data).Module summary and demonstration scenario
Supply estimates are based on user inputs describing
each manufacturer’s anticipated capacity, timing of
expected increases in capacity, and year of vaccine avail-
ability, assuming development success and regulatory
approval. Demand estimates in the form of total doses
required per year are based on the size of the target
population in each country, the maximum level of cover-
age and time taken to reach this level, and the number
of doses in a regimen. Along with the above inputs and
reference data, the model outputs include the year the
vaccine is available for use in each country (from both
supply and approval perspectives), the number of dosesTable 1 Supply and demand module: user inputs for supply p
Parameter name Definition
Manufacturing capacity Describes current known or estimated facility c
Describes timeline of new facilities.
Year of vaccine approval The user determines the year of approval by a
Health Organization (WHO) prequalification, w
prerequisite for availability. The user then selec
is required by each country.demanded, and the number of doses available to meet
demand in any given year.
For the demonstration scenario, it was assumed that
supply would not be constrained by manufacturing capacity
and that all countries would require vaccine prequalification
by WHO. Forty countries in sub-Saharan Africa that expe-
rienced a malaria disease burden in 2006 of 100 deaths
per year or greater, or that experienced a malaria mortality
rate of 10 deaths per 100,000 per year or greater, were
included. The criteria were intended to allow inclusion of
large countries with many cases at a relatively low rate,
and small countries with few absolute cases but which have
a significant rate relative to the population size. The time
horizon modeled in the demonstration scenario was 10 years
of vaccine use, beginning in 2016 (see Additional file 1).
Demand in the demonstration scenario (Figure 2)
assumed a vaccine regimen of three doses delivered to a
target population of infants and a wastage rate of 10%
(see Additional file 1). No product preference or max-
imum acceptable price was modeled. Years between
vaccine approval and country adoption of the modeled
malaria vaccine, maximum coverage, and the time to
reach maximum coverage were benchmarked from
historical data, based on the uptake of Hib vaccine from
2001 to 2010 (either on its own, in the form of aarameters
Input values
apacity. Number of doses
Year available
national regulatory authority (NRA) and World
hich are assurances of vaccine quality as a
ts whether NRA approval or WHO prequalification
Year
Table 2 Supply and demand module: user inputs for demand parameters
Parameter name Definition Input values
Year of vaccine approval The user determines the year of approval by a national
regulatory authority (NRA) and World Health Organization
(WHO) prequalification, which are assurances of vaccine
quality as a prerequisite for availability. The user then
selects whether NRA approval or WHO pre-qualification is
required by each country.
Year
Years between vaccine approval and
country adoption
Identifies time between the first year that a vaccine is available
and the year that each country implements a vaccine.
Number of years
Maximum coverage Describes the largest percentage of the target population
reached in each country. The user can either define the
percentage reached, or use the default settings referencing
the actual coverage levels of other vaccines.
%
Years for each country to reach
maximum coverage
Describes the number of years between implementation
and achievement of maximum coverage.
Number of years
Number of doses per regimen Describes the number of doses required to fully vaccinate
each person at efficacy levels described under the public
health impact module.
3 or 4
Vaccine wastage Describes the proportion of doses that will not be
administered. Vaccine wastage is a percentage set by the
user, but suggestions are provided in the MVM based on
the number of doses per vial, according to WHO projected
vaccine wastage (http://www.who.int/immunization_delivery/
systems_policy/logistics_projected_wastage/en/index.html;
accessed: 2011 Apr 28). The model does not take buffer stock
(a one-time 25% increase of vaccine doses distributed in a
logistics system in the first year of implementation) into
account.
%
Target population The age group in which the vaccine is used: infants
(represented by the annual birth cohort for each country),
5-17 month olds, 1 year olds (yos), 0-4 yos, 1-4 yos, 1-39 yos,
5-39 yos, or the total population
Age range
Product preference In the case of multiple available vaccines, the user may model
scenarios in which particular countries prefer one vaccine over
another.
Product name



























countries 1             7              3             1             5             6            12             1           0              0 
Figure 2 Estimated number of malaria vaccine doses delivered per year over a 10-year period. Numbers of doses delivered are based
upon reports of the use of Hib vaccine to WHO between 2001 and 2010 from 40 countries in sub-Saharan African with significant malaria
burden. The number of countries that began implementation each year is indicated below the x axis (note that there is a delay between the
time each country begins implementation and reaches peak coverage).
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http://www.biomedcentral.com/1471-2334/13/295tetravalent vaccine with DTP, or as a pentavalent vaccine
with DTP and hepatitis B). WHO data on Hib coverage
served as a reference point for the number of years post
vaccine availability that each country began implementa-
tion, each country’s maximum coverage (DTP3 coverage
was selected to represent maximum), and the time it
took for Hib3 to match DTP3 levels [22]. Since malaria
is more commonly recognized as a health threat than
Hib, and because countries have gained experience in
vaccine implementation since Hib introduction began,
unadjusted data from Hib introduction might therefore
underestimate the uptake of a malaria vaccine. The data
were adjusted such that all countries that did not adopt
Hib in the first two years of its availability were modeled
as adopting a malaria vaccine two years earlier than they
adopted Hib. The time each country took to reach max-
imum coverage was not adjusted. If countries did not
introduce Hib by 2010, they were excluded from the
demonstration scenario. The exception was Nigeria,
which appears to be moving more quickly to adopt more
recent vaccines than it did with Hib [23]. Nigeria was as-
sumed to adopt the malaria vaccine midway through the
time horizon analyzed, and reach maximum coverage in
two years (see Additional file 2).
Public health impact estimates
Based on user inputs and reference data on the transmis-
sion level of malaria in each country and the selected vac-
cine characteristics, the principal outputs of the public
health impact module are the estimates of uncomplicated
cases, severe cases, deaths, and DALYs that could be
averted by vaccine use.
The natural history, epidemiology of P. falciparum and
vaccine impact were modeled using a stochastic simulation
model developed at Swiss TPH and described in detail in
previous publications [24-29]. The age structure of the
simulated human populations was based on the number of
people in each of a set of standard age groups in the demo-
graphic surveillance site of Ifakara, Tanzania [30]. Swiss
TPH model parameters were estimated by fitting the model
to field data from a variety of settings across sub-Saharan
Africa [31]. Pre-vaccination transmission intensity was
scaled to give the different required values of the initial
exposures (e.g. 0.1, 1, 10, or 100 infected bites per person
per annum as described below). Pathogenesis and case
management (including hospitalization of severe cases)
were also simulated as described in previous publications
[26,29,32]. Any changes in transmission intensity induced
by a vaccination program (due to herd immunity or other
indirect effects) were captured, but the vectorial capacity
(a mosquito population’s capacity to transmit malaria)
followed the identical periodic pattern as in the absence of
vaccine. The current version of the MVM utilized the key
parameters found to be of interest to developers andpolicymakers in the first version of the MVM - for example,
specific populations in specific transmission settings and
utilization of particular modes of delivery (Table 3).
Reference data
Disease burden Malaria-specific morbidity and mortality
rates were obtained from the WHO for both the entire
population and the population under 5 years of age [34]
and are updated annually. In situations where no data
specific to the under-5 population were available, the total
population’s malaria morbidity and mortality rates were
applied. Projections of future disease burden were based on
each country’s current morbidity rate or current mortality
rate multiplied by the country’s population forecast for
the selected population. Options for changing the future
disease burden, such as from implementation of other
interventions, are described below. Estimates of vaccine
impact on disease burden are based on the levels of trans-
mission in each country, as described below.
Malaria transmission In the MVM, the intensity of trans-
mission is represented by the entomological inoculation
rate (EIR), defined as the product of the human biting rate
of mosquitoes and the proportion of mosquitoes that are
infectious. EIR is measured in the number of infective bites
per person per annum (ibpa). Two sources of data on
transmission were incorporated into the MVM, allowing
the user to choose between them. Data from WHO were in
the form of the percentage of each country’s population at
high or low risk for malaria infection [34]. Alternatively, the
Malaria Atlas Project (MAP) data were in the form of
P. falciparum parasite prevalence [35]. The WHO source
data were not provided in the form of EIR, which is the
required input for transmission for the Swiss TPH model.
The data were converted to EIR using methodology
endorsed by both MAP and an external expert panel
(see Additional file 3). Fortunately, much progress has been
made recently in understanding the relationship between
different measures of transmission [36]. The MVM calcu-
lates the percentage of each country’s population that falls
into each of five EIR levels (0, 0.1, 1, 10, and 100 ibpa).
Since transmission can vary multifold between settings and
the means of measurement are imprecise [37], the EIR
levels listed above were selected to clearly reflect this wide
variation. The user is also free to input future changes in
levels of transmission for countries, for example based
upon the expected impact of other malaria interventions.
Vaccine impact on disease burden
Estimates of the impact of vaccines on disease burden were
based on the parameters of and simulations run in the
previously published, dynamic model of the Swiss TPH,
and integrated with country-specific transmission data in
the MVM. Pre-erythrocytic vaccination was simulated as
Table 3 Public health module user inputs
Parameter name Definition Input values
Type of vaccine Describes the antigens targeted. Options include pre-
erythrocytic (PE), blood-stage (BS), or a combination of these
plus a vaccine component targeting sexual, sporogonic, and/
or mosquito (SSM) antigens to interrupt transmission from an
infected person to the next.
Select one: PE, BS, PE + BS, PE + SSM,
BS + SSM, PE + BS + SSM
Vaccine efficacy Describes the efficacy of the vaccine immediately after
completing the full regimen. For a pre-erythrocytic vaccine,
efficacy against infection is defined as the proportional
reduction in incidence of blood-stage infection. The user
selects the level of efficacy against clinical disease, which is
lower than efficacy against infection (and the model
implements a mapping between the two). For a blood-stage
vaccine, efficacy is defined as the proportional reduction in
blood-stage parasite density. For a vaccine targeting the SSM
antigens, efficacy is defined as the proportion by which the
probability that a mosquito is infected during one bite is
reduced [33].
Select one: 35%, 50%, 60%, 75%, 85%
Decay rate of efficacy against infection Describes the time after vaccination at which the vaccine
protection against infection is half of its initial value. Decay
rate of efficacy assumes an exponential decay of efficacy.
Select one: 2, 4, 10 years
Future malaria transmission Transmission is described as the percent of the population
of the country of interest residing in each of five categories
of entomological inoculation rate (EIR), which is a measure
of how many infectious bites a person receives per year
(ibpa) in a given setting. The starting transmission level for
each country is derived from the reference data described
below. The user can choose to keep transmission fixed at
this level throughout the time period under consideration,
or can enter scenarios of future transmission, for example,
specific to an individual country.
See Additional file 3
Mode of vaccine delivery Describes the means by which the vaccine is delivered to
its target population. The options include routine vaccination
via a country’s routine immunization system and campaign
delivery.
See Table 4
Booster compliance rate Percentage of population originally vaccinated who receive
a single booster dose.
%
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vaccination leads to both a reduction in the proportion of
inoculations from the bites of infected mosquitoes and the
resulting blood-stage infections. This leads to values of effi-
cacy against infection higher than the proportion of clinical
episodes prevented by such a vaccine [39]. Blood-stage
vaccination was simulated by assuming that the vaccine
reduced blood-stage parasite densities while transmission-
blocking vaccines reduce the proportion of blood feeds that
result in infection of the vector [33]. Duration of protection
against infection is modeled as an exponential decay in
vaccine efficacy as previously described [40], and the decay
rate of efficacy against infection is the key variable that was
chosen as a user input in the MVM. Decay rate of efficacy
against infection describes the time after vaccination at
which the vaccine protection against infection is half of its
initial value. Vaccination scenarios were paired with non-
vaccination comparator simulations to provide impact
estimates of the outcomes found to be of greatest interest
from the first version of the MVM: the numbers of cases
(uncomplicated and severe), deaths, and disability-adjustedlife years (DALYs) averted through vaccine use over time
periods of interest.
MVI, Applied Strategies, and Swiss TPH agreed on
possible combinations of input parameters anticipated to
be of interest to vaccine developers and policymakers,
resulting in over 100,000 scenarios to be simulated (Table 4).
Each scenario was run multiple times, and mean frequen-
cies of events were computed in order to reduce stochastic
variability in the estimates of health effects. The results of
these simulations are stored in look-up tables as reference
data in the MVM, drawn upon as necessary according to
the particular combinations of inputs for specific popula-
tions in the scenario chosen by the user (see Additional
files 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16).
Module summary and demonstration scenario
Estimates of the public health impact of a vaccine are
generated based on the type of vaccine, initial efficacy and
decay rate of vaccine efficacy against infection, mode of
vaccine delivery, and transmission setting. The model out-
puts from this module are the total number of events
Table 4 Vaccination strategies generated by Swiss TPH
Strategy name
No vaccination
Routine infants with a boost 2 years later
Routine infants (no boost)
Routine infants with a boost 2 years later PLUS a catch-up of
5–17 month olds (no boost)
Routine infants (no boost) PLUS a catch-up of 5–17 month olds
(no boost)
Routine infants with a boost 2 years later PLUS a catch-up of 1–5 year
olds (no boost)
Routine infants (no boost) PLUS a catch-up of 1–5 year olds (no boost)
Routine infants with a boost 2 years later PLUS a catch-up of 1–39 year
olds (no boost)
Routine infants (no boost) PLUS a catch-up of 1–39 year olds (no boost)
Routine 5–17 month olds with a boost 2 years later
Routine 5–17 month olds (no boost)
Periodic 1–5 year olds every 5 years (no boost) PLUS a catch-up of
6–39 year olds (no boost)
Legend: Strategies reflect different implementation approaches and target
population. “Infants” mean children approximately six weeks of age at first
vaccination. “Routine” vaccination means that it is happening continuously as
individuals reach the target age. “Catch-up” campaign means a one-time, mass
vaccination targeting the indicated age range. “Periodic” campaign means
regular mass vaccinations targeting the indicated age range, at the
indicated frequency.
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DALYs) in the total population or those less than 5 years of
age through use of the vaccine.
For the demonstration scenario, although none of the
current vaccine candidates in trials is expected to meet this
target, a pre-erythrocytic vaccine with an efficacy of 85%
against uncomplicated malaria cases was assumed in light
of the strategic goal for malaria vaccine development set in
2006 [19]. The decay rate of efficacy against infection was
four years. These values of efficacy and its decay were
selected for the demonstration scenario as they were
expected to be broadly consistent with targets set by the
international community [19]. Routine infant immunization
(via the Expanded Program on Immunization) was selected
as the mode of delivery. As described above, the user
enters the projected transmission in each country in the
form of EIR into the MVM. For the demonstration
scenario, three different projections were created to reflect
decreases in transmission from current levels, potentially
due to implementation of existing interventions. The pro-
jection applied to the demonstration scenario used the
MAP-derived EIR distribution across countries, shifting
one-quarter of the population at each EIR level (0, 0.1, 1,
10, and 100 ibpa) into the next lower category (e.g., from
EIR of 10 down to 1). The other two projections shifted
either one-half or three-quarters of the population at each
level to the next lower level of EIR. It was assumed that the
percentage of the population residing in each EIR leveldecreased in a linear fashion to the next lowest level over a
period of five years, and remained constant for the
remaining five years modeled.
Implementation cost and financing requirements
The implementation cost and financing requirements
module estimates the total investment that would be
required to purchase and deliver the vaccine simulated in
the public health impact module, and the cost of each event
averted in 2011 US dollars. User inputs are presented in
Table 5.
Reference data
This module does not include pre-entered reference data.
Module summary and demonstration scenario
Based on the user inputs of vaccine price and implementa-
tion costs, the module generates the total investment
required to achieve the public health gains estimated in the
public health impact module, and calculates the cost per
case, severe case, death, and DALY averted. Depending on
the assumed financing scenario, for example, if donors sup-
port a portion of the purchase and implementation costs,
the model provides a break-down by donor and country
contributions for each year of vaccine use. A discount rate
can be used to calculate the present values of the total
investments, and can be summed to estimate the net
present value.
The demonstration scenario assumed a vaccine price
remaining constant at $5/dose, including insurance and
delivery to the airport of a country as specified by the
consignee. Inflation was not included. This price is broadly
consistent with the assumed cost of other new vaccines
for low-income countries, such as pneumococcal conjugate
and human papilloma virus vaccines (as there is no price
yet determined for any potential malaria vaccine).
In addition to the vaccine price, the implementation
cost modeled was $0.33/dose and injection equipment
costs were $0.07/dose, totaling $1.20/fully immunized
child. Costs were based upon a simulation study of the
cost of introducing a malaria vaccine into the routine
immunization system in Tanzania [41], and were also
consistent with results from a similar study following the
introduction of a pentavalent DTP-hepatitis B-Hib vaccine
in Ethiopia [42]. Results from the demonstration scenario
are presented without discounting and with a discounting
of up to 5%, to cover a range around the most commonly
used rate of 3% in the literature [43].
Table 6 summarizes the assumed values and vaccine
characteristics for the demonstration scenario that were
described throughout the methods section. Assumptions
related to cold chain and personnel were not separately
costed for the demonstration scenario, but instead based
Table 5 Financial module user inputs
Parameter name Definition Input values
Vaccine price The cost of the vaccine in US dollars (USD) as set by the manufacturer,
including insurance and delivery to the airport of a country specified
by the consignee.
$
Cost of injection equipment and disposal The cost of the syringes and waste disposal equipment. $
Cost of vaccine delivery Different costs can be entered for each country, allowing customized
estimates that take into account factors such as the cold-chain capacity
and transport needs of each.
$
Discount rate A distinct discount rate can be entered for the supplier and the donor,
reflecting the cost of capital of each.
%
Financing scenario Users select the financing start and end dates. Years
Users select the level of country co-pay to complement support from
donor organizations. Users can create various financing scenarios.
USD
Nunes et al. BMC Infectious Diseases 2013, 13:295 Page 9 of 15
http://www.biomedcentral.com/1471-2334/13/295upon published analyses which built upon experience with
existing vaccines (e.g. DTP-HepB-Hib) [42,44].
Sensitivity analysis
The MVM allows the user to perform sensitivity analyses
to determine the magnitude of the impact of select factors
on the model outputs. Sensitivity-analysis outputs can be
generated for any given year, or over the entire period
modeled. Sensitivity-analysis results indicate the impact of
the adjusted parameter(s) on the public health and financial
estimates. The following model inputs can be increased or
decreased by a percent of the value set by the user: country
willingness to pay (maximum price); discount rate; price of
vaccine or injection equipment; and percentage of product
wastage. Country adoption and product availability inputs
can be increased or decreased by a number of years relative
to a baseline. Alternatively, for those parameters not
included in the formal sensitivity analysis, such as vaccine
efficacy, decay rate of efficacy, transmission, or the use of a
booster dose, model outputs from several scenarios can be
saved and compared.
Results
The demonstration scenario was run to illustrate the
functionality of the MVM. The inputs selected for this
scenario were described above in the Methods section. The
outputs of the demonstration scenario are presented below
(see Additional file 17).
Supply and demand module
Based on the historical data from Hib, adapted as described
above, in its first two years of use, over 16 million (M)
doses of malaria vaccine were required to meet demand,
plateauing at 93 M between years 7 and 10 (Figure 2). Over
the course of 10 years of vaccine use, the MVM outputs
from the demonstration scenario indicated that a total of
532 M doses would be required in the 40 African countries
in the analysis.Public health impact module
The estimated number of doses of vaccine required from
the supply and demand module was used as an input for
the calculation of public health impact. While the under-
lying calculations were made for each country, the results
were presented at an aggregate level to give a sense of
impact across all of sub-Saharan Africa.
Based on the demonstration scenario inputs, an esti-
mated 150.4 M uncomplicated cases of malaria would be
averted over 10 years of vaccine use (Table 7), with 44.3 M
averted in year 10 alone (Figure 3). Over this same period,
5.1 M severe cases of malaria would be averted, along with
1.1 M deaths and 28.4 M DALYs. The number of severe
cases, deaths, and DALYs averted annually increased over
the whole time period, with the largest number seen in the
final year: 1.3 M, 258,000, and 6.9 M, respectively (Figure 3).
It can be useful to present these data as ratios of the
number of events averted per 1,000 vaccine recipients, as
well. Averaged over the 10-year time period, the inputs for
the demonstration scenario led to 943 uncomplicated cases
averted/1,000 vaccinees, 32 severe cases averted/1,000
vaccinees, 7 deaths averted/1,000 vaccinees, and 178 DALYs
averted/1,000 vaccinees (Table 7).
Implementation cost and financing module
The cost per event averted was calculated in the MVM for
each year of the analysis using the non-discounted total
investment (vaccine price plus injection equipment plus
delivery costs). It could also be informative to consider the
present value of the investments, calculating the cost per
event averted with a discounted number. These data are
presented in Table 7 as the aggregate over the entire period.
In the demonstration scenario, the undiscounted cost was,
in 2011 US dollars, $19 per uncomplicated malaria case
averted, $561 for each severe case averted, $2,690 for each
death averted, and $101 for each DALY averted. After
discounting the total investments at 5% to a net present
value in 2011 US dollars, the costs were $11, $309, $1,482,
and $56, respectively.
Table 6 Summary of values & vaccine characteristics in the demonstration scenario
Parameter name Assumed value Rationale or source, as applicable
Supply and demand module
Time period modeled 10 years Mid-range period that is long enough to allow for
countries to implement and observe impact; a
longer period would increase model uncertainty
Year of vaccine approval 2016 Date in the medium term selected to avoid the
increased model uncertainty associated with
longer time horizons
Countries 40 African countries with high disease burden 100 deaths/year or malaria mortality rate of 10
deaths per 100,000 per year or greater [45]
Years between vaccine approval
and country adoption
0-10, based on each country’s adoption of
Haemophilus influenza type B (Hib) vaccine
(see Methods)
See Methods under “Supply and demand forecast”
Maximum coverage 3rd dose of diphtheria-tetanus-pertussis vaccine
(DTP3) level of each country, as projected
(see Methods)
Demonstration scenario assumes routine
vaccination (below); DTP3 coverage is therefore
a realistic estimate of what might be achieved
Years for each country to reach
maximum coverage
1 to 3, based upon each country’s adoption of
Hib vaccine (see Methods)
See Methods under “Supply and demand forecast”
Number of doses per regimen 3 Consistent with other, licensed vaccines
Vaccine wastage 10% (assumed 2 doses/vial) Consistent with other, licensed vaccines
Target population Infants Infants carry the greatest burden of disease [20]
Public health module
Type of vaccine Pre-erythrocytic The most advanced candidate is a pre-erythrocytic
vaccine and therefore the most likely type to first
reach 85% efficacy
Vaccine efficacy against clinical disease 85% Consistent with the strategic goal of the 2006
Malaria Vaccine Technology Roadmap
Decay rate of efficacy against infection 4 years Consistent with the strategic goal of the 2006
Malaria Vaccine Technology Roadmap
Future malaria transmission ¼ of the population in each Entomological
Inoculation Rate category shifted to the
next lowest by 2020 (0, 0.1, 1, 10, 100)
Assumes continued scale-up of other interventions
and progress toward global targets
Mode of vaccine delivery Routine infant immunization
(Expanded Program on Immunization (EPI))
Infants carry the greatest burden of disease and
are routinely vaccinated via the EPI system
Booster compliance rate Not used in demo. scenario None assumed
Financial module
Vaccine price $5/dose There is no price yet determined for any potential
malaria vaccine; consistent with the cost of other
new vaccines for low-income countries
Cost of injection equipment and disposal $0.07/dose See Methods section under Implementation cost
and financing requirements [42,44,46]
Cost of vaccine delivery, including: $0.33/dose Consistent with experience with pentavalent
vaccine in Ethiopia [42,44,46]
• Cold chain requirement of 2-8°C
• Personnel and training
Discount rates 0% and 5% Consistent with the full range of rates used in the
sub-Saharan context [43]
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Lower vaccine efficacy and a larger decrease in malaria
transmission were considered (Figure 4 and Table 8).
Reducing the efficacy to 75% decreased the estimated
number of uncomplicated cases averted over 10 years by
14%, from 150 M to 130 M. Similarly, the total number ofsevere cases, deaths, and DALYs averted were predicted to
decrease by 14%, 19%, and 18%, respectively (data not
shown). While the total investment would remain the same,
fewer events would be prevented, increasing the
undiscounted (and discounted) cost/event averted from
$19 ($11) per uncomplicated case to $22 ($12). The cost
Table 7 Cumulative number and ratio of malaria events averted, and cost per event averted
Total events averted







Uncomplicated malaria 150 943 19 11
Severe malaria 5 32 561 309
Death 1 7 2,690 1,482
DALY 28 178 101 56
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death averted to $3,340 ($1,840), and per DALY averted to
$124 ($68).
Great progress has been made over the past decade in
scaling up the current malaria control interventions [4].
While our demonstration scenario shifted one-quarter of
the population in each EIR category to the next lower level
of risk, it is possible that national malaria control programs
and their partners will achieve greater success in lowering
transmission. To understand the potential public health
gains that could be attributed to the vaccine in a setting
with lower transmission, and therefore many fewer cases to
avert, we also modeled the scenario described in the
Methods section in which one-half of the population in
each EIR category is shifted to the next lowest level of risk.
MVM outputs indicated that such a shift would lead
to approximately 21% fewer events averted across all
























































Figure 3 Annual malaria events averted in 40 high-burden African co
A) uncomplicated cases; B) severe cases; C) deaths; D) DALYs averted by u
decay rate of 4 years over 10 years in sub-Saharan Africa.Discussion
This paper describes a collaborative effort to develop a mal-
aria vaccine model of supply, demand, public health impact,
and costs designed for use by diverse audiences at country,
regional, and global levels and based upon simulations of
vaccine impact on public health outcomes from the Swiss
TPH model. The functionality of the model was demon-
strated by estimating the impact and implementation costs
associated with a hypothetical vaccine broadly consistent
with international targets. Modeled estimates suggest that
such a malaria vaccine could have an important public
health impact, and it will be important to compare the
model functionality and results with those from other
malaria vaccine models as they become available.
The model was designed to have the flexibility to include
user inputs, which could allow for the incorporation of new
data as they become available. For example, the user can
input any scenario for future malaria transmission, whether

















































untries by the simulated vaccine. MVM projections of the number of
se of an 85% efficacious pre-erythrocytic vaccine with an efficacy
Table 8 Impact of efficacy and transmission setting on












Efficacy 13 16 3 (2)
Transmission 21 26 5 (3)
Both 33 47 9 (5)
Severe cases
Efficacy 14 16 91 (50)
Transmission 21 26 145 (80)
Both 31 46 258 (142)
Deaths
Efficacy 19 24 650 (358)
Transmission 21 26 711 (392)
Both 36 57 1528 (842)
DALYs
Efficacy 18 22 23 (12)
Transmission 21 26 27 (14)
Both 35 54 55 (30)
Legend: Table shows the results from the scenarios modeled as part of the
sensitivity analysis. Percentage decrease or increase in public health impact or
cost is relative to the demonstration scenario results, presented in Table 7.
“Efficacy” refers to a decrease in the vaccine efficacy from 85% in the
demonstration scenario to 75%. “Transmission” refers to a change in future
transmission from the demonstration scenario, in which one-quarter of the
population in each category of risk was shifted to the next lowest category, to
the sensitivity analysis, in which one-half the population was at reduced risk of
infection. “Both” refers to a scenario in which both efficacy and transmission












1 2 3 4 5 6 7 8 9 10
85% PEV quarter step
85% PEV half step
75% PEV quarter step
75% PEV half step
Figure 4 Implications of changing vaccine efficacy or transmission intensity on impact. The impact of vaccine efficacy and transmission
setting on the potential number of uncomplicated malaria cases averted annually over a 10-year period of vaccine use. The demonstration
scenario of 85% efficacy and a transmission setting in which the risk level (EIR category) of one-quarter of the population at risk was reduced
averted the most cases (●), followed by 85% efficacy at a setting in which the risk level of one-half the population at risk was reduced (▲), 75%
efficacy at the transmission setting in which one-quarter of the population experienced reduced risk (■), and 75% efficacy at a transmission
setting in which one-half the population at risk experienced a reduction in transmission (×).
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interventions on transmission. Another example of user-
entered data illustrated in the demonstration scenario was
the use of historical data from the implementation of the
Hib vaccine as inputs for country adoption.
Future versions of the model could be applied to other
types of malaria vaccines that are being considered or that
are currently in research and development—for example,
future versions of the model could include different
efficacy levels, delivery strategies, or additional target pop-
ulations, such as pregnant women. The most clinically
advanced vaccine candidate is RTS,S, in development by
GlaxoSmithKline (GSK) and MVI. Results of the RTS,S
Phase III trial for efficacy and safety, indicate that 3 doses
of the RTS,S vaccine candidate reduced clinical and severe
malaria over the first year of follow-up by 56% and
47%, respectively, in children 5-17 months of age at first
vaccination; and 31% and 37%, respectively, in infants
6-12 weeks of age at first vaccination [18,47]. If the re-
quired regulatory and public health information, including
safety and efficacy data from the Phase III program, are
deemed satisfactory, the WHO has indicated that a policy
recommendation for the RTS,S malaria vaccine candidate
is possible as early as 2015, paving the way for decisions
by African nations regarding large-scale implementation
of the vaccine through their national immunization pro-
grams [48]. The type of estimates generated by the MVM
will be of great interest to policymakers at both the global
and country levels to inform decisions around RTS,S.Model design
The balancing of a comprehensive approach with simpli-
city can lead to models that attempt to include all consid-
erations and empirical field data, yet lose their usability
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vector-borne, parasitic disease, like malaria, is not well-
reflected by overly simplified assumptions. Collaborators
settled on a compromise to integrate the strengths of a
comprehensive and computationally intensive model
associating epidemiological patterns and vaccine charac-
teristics with impact from Swiss TPH with simpler,
specially designed, component modules for less computa-
tionally intensive elements such as the number of individ-
uals that might be immunized. The MVM integrates
pre-defined inputs from Swiss TPH with the other
modules through a tailor-made user interface, providing
a seamless means of inputting data and generating
outputs.
While the MVM was designed to allow users the flexi-
bility to enter as much of their own data as possible
and choose between various input options described in
Tables 1-5, the limitation is that only the simulations run
by Swiss TPH can be accessed by users. It is possible
for the MVM developers to upgrade the model with
additional simulations, as is currently planned. The work
required to design a model that is both comprehensive
and easy to use should not be underestimated, however.
Another limitation of the model is that it requires a large
amount of storage (2.98 gigabytes), by today’s standards,
on the user’s computer, the majority of which (90%) is
used to hold the Swiss TPH simulation reference data.Uses and outputs
The MVM interface provides an accessible means to enter
data and generate results, which are presented in straight-
forward outputs. The outputs of the MVM were designed
to address questions arising from three distinct audiences:
country policymakers, regional and global policymakers,
and vaccine developers. The MVM can provide country
policymakers with estimates of impact and costs of
malaria vaccines tailored to their local transmission
setting, and based on local assumptions about implemen-
tation, such as delivery strategy, coverage, and cost. One
strength of the MVM is the simultaneous generation of
estimates for individual and multiple countries, which
regional and global policymakers may use to support the
setting of standards on the use of a malaria vaccine. In
addition to the graphical data in the interface, both
reference data and model result reports can be easy
downloaded into Excel or pdf files. The types of outputs
generated by the MVM are relevant to policymakers
seeking information on the role of malaria vaccines as
complements to other strategies to address malaria. For
malaria vaccine developers and global organizations, the
MVM can help inform trade-offs between various product
characteristics, delivery options, impact, and costs, as well
as supply and demand considerations.Parameters
The MVM includes pre-entered reference parameters
where possible, while allowing users the flexibility to enter
a wide range of scenario-specific parameters when desired.
The number of parameters and associated ranges led to
more than 100,000 scenarios from Swiss TPH. It should be
noted that, while all-cause childhood mortality is not an
explicit component of the MVM, changes in all-cause
mortality can be accounted for using the regularly updated
demographic data. A number of the parameters and associ-
ated assumptions in the MVM merit specific discussion.
There is no universally agreed-upon means for converting
malaria transmission data from WHO and the Malaria
Atlas Project into EIR for each country, though much
progress has been made recently in understanding the
relationship between different measures of transmission
[36]. Furthermore, there is no standard for projecting how
transmission may change for each country. MVI sought
the participation and validation of expert collaborators
and arrived at an approach, as described in Additional file
3, which transparently translates existing data on the per-
centage of the population at risk into EIR-equivalents.
Users are able to customize assumptions of underlying
and changing transmission. Perhaps in the future there
will be greater standardization on one means of measuring
the prevalence and transmission of malaria.
One of the strengths brought by building upon the Swiss
TPH model is that it is parameterized with extensive field
data on malaria. There is always uncertainty in models, the
quantification of input parameters and assumptions of their
interrelations, which is not straightforward. For instance,
mathematical models of malaria vaccines (Swiss TPH and
Imperial College London), currently assume that efficacy
decays exponentially. It is yet not established whether an
exponential model reflects the decay in true vaccine
protection.
Faced with multiple public health interventions and vac-
cines, and given the current funding environment, health
economic data is becoming an increasingly important
consideration in adoption decisions. The WHO uses cost-
effectiveness thresholds based on gross domestic product
to evaluate interventions [49], and any malaria vaccine will
need to be evaluated in light of such thresholds. The price
of new vaccines, rather than the cost of implementation,
has been found to be a major driver of cost-effectiveness
[50]. The vaccine price of $5 a dose was selected as the in-
put for the demonstration scenario because it is consistent
with the price of other novel vaccines (as there is no price
yet determined for any potential malaria vaccine), but it will
be critical that the cost borne by countries fit into malaria
budgets that includes other type of interventions.
The purpose of the demonstration scenario presented in
this paper was to illustrate the functionality of the model,
rather than to forecast when individual countries might
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tation by countries, and time to maximum coverage, are
important drivers of impact. Figure 2 illustrates the degree
to which the rate of demand for doses can vary after a new
vaccine becomes available. The vaccine adoption decisions
of large countries, particularly those that also have a large
disease burden, can greatly influence estimates of supply
and demand, public health impact, and financial require-
ments. For example, if Nigeria had implemented the vac-
cine in the 8th year of its availability (rather than the 5th, as
modeled), 18% fewer cases and 15% fewer deaths would
have been averted overall in the demonstration scenario.
Conclusion
The field of malaria is rapidly changing, with malaria trans-
mission decreasing, partly due to other effective interven-
tions, and the potential for an efficacious vaccine on the
horizon. These changes are important to those developing
malaria vaccines as well as those who make policy decisions
on the use and financing of vaccines. This paper presents a
new model on supply, demand, public health impact, and
costs of malaria vaccines to inform this changing field. The
model is designed to be user-friendly, is built upon
the Swiss TPH model simulations, and takes into account
the questions of interest to policymakers at the country,
regional, and global levels, as well as vaccine developers.
Results from a demonstration scenario indicate that a hypo-
thetical vaccine with an efficacy of 85% against clinical dis-
ease could have substantial public health impact. Following
validation exercises, the current MVM, future iterations,
and other models like it could provide additional insight to
ensure investments are well-targeted and could then inform
the critical public health decisions that policymakers at na-
tional, regional, and global levels must make on the optimal
means to prevent the millions of malaria cases each year.
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